SCHEMBL19687

SCHEMBL19687

CC(=O)Nc1nnc(S(=O)(=O)Cl)s1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 12/20 0.70
CA2 P00918 12/20 0.70
CA9 Q16790 8/20 0.70
CA4 P22748 8/20 0.70
CA12 O43570 3/20 0.70
CA3 P07451 3/20 0.70
CA6 P23280 3/20 0.70
CA5A P35218 3/20 0.70
CA7 P43166 3/20 0.70
CA13 Q8N1Q1 3/20 0.70
CA14 Q9ULX7 3/20 0.70
CA5B Q9Y2D0 3/20 0.70
MEN1 O00255 1/20 0.70
CA11 O75493 1/20 0.70
THRB P10828 1/20 0.70
BLM P54132 1/20 0.70
KMT2A Q03164 1/20 0.70
SMN1; SMN2 Q16637 1/20 0.70
TDP1 Q9NUW8 1/20 0.70
GLS O94925 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18100211 0.84 CA1 (0.72) CA1CA2CA9CA4CA12
SCHEMBL11561420 0.83 CA2 (0.51) CA1CA2CA9CA4CA12
SCHEMBL14194327 0.82 CA1 (0.70) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL23219 0.82 CA1 (1.00) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL2557036 0.82 CA1 (1.00) CA1CA2CA9CA4CA12
Hydrochloric Acid SCHEMBL10464123 0.82 CA1 (0.70) CA1CA2CA9CA4CA12
SCHEMBL17850506 0.81 CA1 (0.72) CA1CA2CA9CA4CA12
SCHEMBL11560223 0.81 CA1 (0.47) CA1CA2CA9CA4CA12
Acetazolamide Sodium SCHEMBL40813 0.81 CA1 (0.68) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL1998362 0.81 CA1 (0.97) CA1CA2CA9CA4CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119241471-A Preparation method and application of 2-acetamido-5-chlorosulfonyl-1, 3, 4-thiadiazole 北京斯利安药业有限公司 2025-01-03 CN claimed
CN-115974814-B Preparation method and application of 2-acetamido-5-chlorosulfonyl-1, 3, 4-thiadiazole 北京斯利安药业有限公司 2024-08-20 CN claimed
CN-115974814-A Preparation method and application of 2-acetamido-5-chlorosulfonyl-1, 3, 4-thiadiazole 北京斯利安药业有限公司 2023-04-18 CN claimed
CN-119241471-A Preparation method and application of 2-acetamido-5-chlorosulfonyl-1, 3, 4-thiadiazole 北京斯利安药业有限公司 2025-01-03 CN disclosed
CN-119241471-A Preparation method and application of 2-acetamido-5-chlorosulfonyl-1, 3, 4-thiadiazole 北京斯利安药业有限公司 2025-01-03 CN disclosed
CN-119241471-A Preparation method and application of 2-acetamido-5-chlorosulfonyl-1, 3, 4-thiadiazole 北京斯利安药业有限公司 2025-01-03 CN disclosed
CN-115974814-B Preparation method and application of 2-acetamido-5-chlorosulfonyl-1, 3, 4-thiadiazole 北京斯利安药业有限公司 2024-08-20 CN disclosed
CN-115974814-B Preparation method and application of 2-acetamido-5-chlorosulfonyl-1, 3, 4-thiadiazole 北京斯利安药业有限公司 2024-08-20 CN disclosed
CN-115974814-B Preparation method and application of 2-acetamido-5-chlorosulfonyl-1, 3, 4-thiadiazole 北京斯利安药业有限公司 2024-08-20 CN disclosed
CN-117447423-A Preparation method of thiadiazolyl sulfonyl chloride compounds and thiadiazolyl sulfonamide compounds 北京斯利安药业有限公司 2024-01-26 CN disclosed
WO-2023094827-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 WO disclosed
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
EP-1904466-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006760-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed
US-4940793-A Pharmacologically active piperazino derivatives RAVIZZA S.P.A. (IT) 1990-07-10 US disclosed
EP-0171636-A1 Pharmacologically active piperazino derivatives and the process for their preparation RAVIZZA S.p.A. (IT) 1986-02-19 EP disclosed
US-4255182-A PRE- AND POSTEMERGENCE HERBICIDES VELSICOL CHEMICAL CORPORATION (US) 1981-03-10 US disclosed
US-4237130-A DIURETICS, HYPOTENSIVE AGENTS MERCK & CO., INC. (US) 1980-12-02 US disclosed
US-3941804-A 1-Heteroarylsulphonyl-2-imino-imidazolidines CIBA-GEIGY CORPORATION (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 CA1 3286/4885CA2 1243/4885CA9 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.